Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
SF1670
Cat. No.:
OB0225LY-0366
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
SF1670 is a small molecule specific PTEN inhibitor.
Synonym:
PTP CD45 inhibitor; PTPase CD45 Inhibitor; 345630-40-2; N-(9,10-Dihydro-9,10-dioxo-2-phenanthrenyl)-2,2-dimethyl-propanamide; N-(9,10-Dioxo-9,10-dihydrophenanthren-2-yl)pivalamide; Propanamide, N-(9,10-dihydro-9,10-dioxo-2-phenanthrenyl)-2,2-dimethyl-
CAS No.:
345630-40-2
Compound CID:
9926586
Formula:
C19H17NO3
Formula Weight:
307.34
Specification
Relative Density:
1.271 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
SF1670 can be used in cell biology research or play an important role in drug screening.
Library Information
Targets:
PTEN; Phosphatase
Pathways:
PI3K/Akt/mTOR signaling; Metabolism; Autophagy
Plate Number:
AOCL-5
Plate Location:
f11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
30.7 mg/mL; 100 mM
